Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00695097 · ClinicalTrials.gov registry record · NA
The Effect of Rituximab on the Development of Anti-Donor Antibodies
A NA study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT00695097 is a NA study that has completed, run by University of California, San Francisco. The registered enrollment target is 18 participants.
The verdict
NCT00695097, a NA study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
The aim of the study is to find out if Rituximab, which is an antibody against specific white cells involved in rejection, when combined with standard anti-rejection treatment can more effectively reverse the rejection process. Our hypothesis is that with acute rejection there is activation of B cells and the subsequent development of anti-donor antibodies that ultimately lead to graft loss. More effective therapy targeted at B cells may abort the development of anti-HLA antibodies, prevent renal injury and have a favorable effect on long-term graft outcome.
Interventions
- DRUG Rituximab
- DRUG No Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2004-08 |
| Est. Completion | 2010-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00695097
The ClinicalTrials.gov registry entry for NCT00695097 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT00695097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00695097 about?
NCT00695097 is a clinical study titled "The Effect of Rituximab on the Development of Anti-Donor Antibodies". The aim of the study is to find out if Rituximab, which is an antibody against specific white cells involved in rejection, when combined with standard anti-rejection treatment can more effectively reverse the rejection process. Our hypothesis is that with acute rejection there is activation of B ce...
What is the current status of trial NCT00695097?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2004-08. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00695097?
The interventions under investigation include: Rituximab (DRUG), No Rituximab (DRUG).
Who is sponsoring clinical trial NCT00695097?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.